ClinicalTrials.Veeva

Find clinical trials for Triple Negative Breast Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Toronto, ON, CAN:

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Enrolling
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Datopotamab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 46 other locations

The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer....

Active, not recruiting
Breast Cancer
Drug: CFI-400945
Drug: Durvalumab

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada and 4 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Niraparib
Drug: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Toronto, Ontario, Canada and 226 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Paclitaxel
Drug: Gemcitabine

Phase 3

Gilead Sciences
Gilead Sciences

Toronto, Canada and 506 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Toronto, Canada and 508 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Enrolling
Breast Cancer
Drug: Carboplatin
Drug: Nab-paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 273 other locations

after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Gemcitabine
Biological: Pembrolizumab

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Toronto, Ontario, Canada and 121 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 357 other locations

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 275 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Toronto, Ontario, Canada and 192 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems